Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1-Reference-Cited by-同舟云学术

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1

Published:2019-01 Issue:1 Volume:18 Page:94-101
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

McColley Susanna A.,Konstan Michael W.,Ramsey Bonnie W.,Stuart Elborn J.,Boyle Michael P.,Wainwright Claire E.,Waltz David,Vera-Llonch Montserrat,Marigowda Gautham,Jiang John G.,Rubin Jaime L.

Funder

Vertex Pharmaceuticals

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Reference25 articles.

1. Cystic fibrosis pulmonary exacerbations;Ferkol;J Pediatr,2006

2. Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice;Justicia;Expert Rev Respir Med,2015

3. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis;Konstan;J Pediatr,2007

4. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation;Sanders;Am J Respir Crit Care Med,2010

5. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis;Sanders;Pediatr Pulmonol,2010

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric Lung Transplantations: New Possibilities and Challenges in Treatment of Children With End-Stage Respiratory Failure;Transplantation Proceedings;2024-05

2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del);Cochrane Database of Systematic Reviews;2023-11-20

3. Evolución clínico funcional de pacientes con fibrosis quística tratados con lumacaftor/ivacaftor en un centro pediátrico. Serie de caso;Archivos Argentinos de Pediatria;2023-10-01

4. Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective;The Lancet Respiratory Medicine;2023-10

5. The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting;Respiratory Research;2023-08-11